내분비 검사 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2032년)

The global demand for Endocrine Testing Market is presumed to reach the market size of nearly USD 28.54 Billion by 2032 from USD 12.61 Billion in 2023 with a CAGR of 9.5% under the study period 2024 - 2032.

Endocrine testing involves diagnostic procedures to assess the endocrine system, which regulates hormones within the body. These tests measure hormone levels in blood, urine, or saliva samples to detect abnormalities or imbalances related to diabetes, thyroid disorders, and reproductive health issues. They aid in diagnosing and monitoring endocrine disorders and guiding appropriate treatment.

MARKET DYNAMICS

The growing prevalence of endocrine disorders, like diabetes, thyroid disorders, and hormonal imbalances, is driving the demand for diagnostic tests to assess endocrine function. With the ongoing global prevalence of chronic diseases continuing to rise, there is a growing need for accurate and timely diagnosis of endocrine disorders. Endocrine testing, a crucial tool in this process, aids in early detection and intervention, guiding treatment decisions and improving patient outcomes. Moreover, advancements in diagnostic technologies, such as immunoassays, chromatography, and molecular diagnostics, are expanding the capabilities and accuracy of endocrine testing methods, further driving market growth. Additionally, the growing aging population and changing lifestyles characterized by sedentary behavior and unhealthy dietary habits contribute to the rise in endocrine disorders, increasing the demand for endocrine testing services. Furthermore, integrating endocrine testing into routine health screenings and wellness programs drives market expansion by facilitating early detection and intervention for endocrine disorders. Moreover, supportive government initiatives to raise awareness about endocrine health and improve access to healthcare services are fueling market growth by promoting routine testing and screening for endocrine disorders. However, high costs associated with advanced testing methods, reimbursement constraints, and regulatory hurdles will likely hinder market growth to some extent.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of endocrine testing. The growth and trends of endocrine testing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the endocrine testing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Test Type

• Estradiol (E2) Test
• Follicle Stimulating Hormone (Fsh) Test
• Human Chorionic Gonadotropin (Hcg) Hormone Test
• Luteinizing Hormone (Lh) Test
• Dehydroepiandrosterone Sulfate (Dheas) Test
• Progesterone Test
• Testosterone Test
• Thyroid Stimulating Hormone (Tsh) Test
• Prolactin Test
• Cortisol Test
• Insulin Test
• Others

By Technology

• Tandem Mass Spectrometry
• Immunoassay
• Monoclonal & Polyclonal Antibody Technologies
• Sensor Technology
• Clinical Chemistry
• Others

By End-Use

• Hospitals
• Commercial Laboratories
• Ambulatory Care Centers
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Endocrine Testing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Endocrine Testing market include Abbott Laboratories, AB Sciex, Agilent Technologies Inc., bioMerieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Ortho Clinical Diagnostics. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . ENDOCRINE TESTING - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Test Type
  • 3.7.2 Market Attractiveness Analysis By Technology
  • 3.7.3 Market Attractiveness Analysis By End-use
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ENDOCRINE TESTING MARKET ANALYSIS BY TEST TYPE

• 5.1 Overview by Test Type
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Test Type
• 5.4 Estradiol (E2) Test Historic and Forecast Sales by Regions
• 5.5 Follicle Stimulating Hormone (FSH) Test Historic and Forecast Sales by Regions
• 5.6 Human Chorionic Gonadotropin (hCG) Hormone Test Historic and Forecast Sales by Regions
• 5.7 Luteinizing Hormone (LH) Test Historic and Forecast Sales by Regions
• 5.8 Dehydroepiandrosterone Sulfate (DHEAS) Test Historic and Forecast Sales by Regions
• 5.9 Progesterone Test Historic and Forecast Sales by Regions
• 5.10. Testosterone Test Historic and Forecast Sales by Regions
• 5.11 Thyroid Stimulating Hormone (TSH) Test Historic and Forecast Sales by Regions
• 5.12 Prolactin Test Historic and Forecast Sales by Regions
• 5.13 Cortisol Test Historic and Forecast Sales by Regions
• 5.14 Insulin Test Historic and Forecast Sales by Regions
• 5.15 Others Historic and Forecast Sales by Regions

6 . GLOBAL ENDOCRINE TESTING MARKET ANALYSIS BY TECHNOLOGY

• 6.1 Overview by Technology
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Technology
• 6.4 Tandem Mass Spectrometry Historic and Forecast Sales by Regions
• 6.5 Immunoassay Historic and Forecast Sales by Regions
• 6.6 Monoclonal & Polyclonal Antibody Technologies Historic and Forecast Sales by Regions
• 6.7 Sensor Technology Historic and Forecast Sales by Regions
• 6.8 Clinical Chemistry Historic and Forecast Sales by Regions
• 6.9 Others Historic and Forecast Sales by Regions

7 . GLOBAL ENDOCRINE TESTING MARKET ANALYSIS BY END-USE

• 7.1 Overview by End-use
• 7.2 Historical and Forecast Data
• 7.3 Analysis by End-use
• 7.4 Hospitals Historic and Forecast Sales by Regions
• 7.5 Commercial Laboratories Historic and Forecast Sales by Regions
• 7.6 Ambulatory Care Centers Historic and Forecast Sales by Regions
• 7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL ENDOCRINE TESTING MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE ENDOCRINE TESTING COMPANIES

• 9.1. Endocrine Testing Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF ENDOCRINE TESTING INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Abbott Laboratories
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. AB Sciex
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Agilent Technologies Inc.
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. bioMerieux SA
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Bio-Rad Laboratories Inc.
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. DiaSorin S.p.A.
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. F. Hoffmann-La Roche Ltd.
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Laboratory Corporation of America Holdings
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Quest Diagnostics Inc.
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. Ortho Clinical Diagnostics
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies